| Connective Tissue Growth Factor (CTGF) ELISA Kit, Recombinant, Antibody | |
| CTGF Human ELISA Kit | |
CTGF plays a role in severe hypertrophic cardiomyopathy and heart failure |
|
|
|
CTGF (Human) ELISA Kit SK00726-01 had been used by Dr. Saminathan A and Dr. Murray C. Meikle on research paper, Engineering three-dimensional constructs of the periodontal ligament in hyaluronan-gelatin hydrogel films and a mechanically active environment. J Periodontal Res. 2013 Dec;48(6):790-801 , PMID: 23581542 |
|
Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction |
|
| IMS:
Myocardial CCN2/CTGF is induced in heart failure of various etiologies. However, its role in the pathophysiology of left ventricular (LV)remodeling after myocardial infarction (MI) remains unresolved. The current study explores the role of CTGF in infarct healing and LV remodeling in an animal model and in patients admitted for acute ST-elevation MI. METHODS AND RESULTS: Transgenic mice with cardiac-restricted overexpression of CTGF (Tg-CTGF) and non-transgenic littermate controls (NLC) were subjected to permanent ligation of the left anterior descending coronary artery. Despite similar infarct size (area of infarction relative to area at risk) 24 hours after ligation of the coronary artery in Tg-CTGF and NLC mice, Tg-CTGF mice disclosed smaller area of scar tissue, smaller increase of cardiac hypertrophy, and less LV dilatation and deterioration of LV function 4 weeks after MI. Tg-CTGF mice also revealed substantially reduced mortality after MI. Remote/peri-infarct tissue of Tg-CTGF mice contained reduced numbers of leucocytes, macrophages, and cells undergoing apoptosis as compared with NLC mice. In a cohort of patients with acute ST-elevation MI (n = 42) admitted to hospital for percutaneous coronary intervention (PCI) serum-CTGF levels (s-CTGF) were monitored and related to infarct size and LV function assessed by cardiac MRI. Increase in s-CTGF levels after MI was associated with reduced infarct size and improved LV ejection fraction one year after MI, as well as attenuated levels of CRP and GDF-15. CONCLUSION: Increased myocardial CTGF activities after MI are associated with attenuation of LV remodeling and improved LV function mediated by attenuation of inflammatory responses and inhibition of apoptosis. |
|
| Gravning J, et al. PLoS One. 2012;7(12):e52120. doi: 10.1371/journal.pone.0052120. Epub 2012 Dec 20. | |
CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure |
|
| Hypertrophic cardiomyopathy (HCM) is the most common inherited primary myocardial disorder. HCM is characterized by interstitial fibrosis and excessive accumulation of extracellular matrix (ECM) proteins. Fibrosis in HCM has been associated with impaired cardiac function and heart failure, and has been considered a key substrate for ventricular arrhythmias and sudden death. The molecular triggers underpinning ECM production are not well established. We have previously developed a double-mutant mouse model of HCM that recapitulates the phenotype seen in humans with multiple mutations, including earlier onset of the disease, progression to a dilated phenotype, severe heart failure and premature mortality. The present study investigated the expression of ECM-encoding genes in severe HCM and heart failure. Significant upregulation of structural Fn1, regulatory Mmp14, Timp1, Serpin3A, SerpinE1, SerpineE2, Tgfβ1, and Tgfβ2; and matricellular Ccn2, Postn, Spp1, Thbs1, Thbs4, and Tnc was evident from the early, pre-phenotype stage. Non-myocytes expressed ECM genes at higher levels than cardiomyocytes in normal and diseased hearts. Synchronous increase of secreted CCN2 and TIMP1 plasma levels and decrease of MMP3 levels were observed in end-stage disease. CCN2 protein expression was increased from early disease in double-mutant hearts and played an important role in ECM responses. It was a powerful modulator of ECM regulatory (Timp1 and SerpinE1) and matricellular protein-encoding (Spp1, Thbs1, Thbs4 and Tnc) gene expression in cardiomyocytes when added exogenously in vitro. Modulation of CCN2 (CTGF, connective tissue growth factor) and associated early ECM changes may represent a new therapeutic target in the treatment and prevention of heart failure in HCM. | |
| Tsoutsman T, et al. J Mol Cell Cardiol. 2013 Jun 10. pii: S0022-2828(13)00197-1. doi: 10.1016/j.yjmcc.2013.05.019. [Epub ahead of print] | |
Connective tissue growth factor is a new ligand of epidermal growth factor receptor |
|
| Chronic kidney disease is reaching epidemic proportions worldwide and there is no effective treatment. Connective tissue growth factor (CCN2) has been suggested as a risk biomarker and a potential therapeutic target for renal diseases, but its specific receptor has not been identified. Epidermal growth factor receptor (EGFR) participates in kidney damage, but whether CCN2 activates the EGFR pathway is unknown. Here, we show that CCN2is a novel EGFR ligand. CCN2 binding to EGFR extracellular domain was demonstrated by surface plasmon resonance. CCN2 contains four distinct structural modules. The carboxyl-terminal module (CCN2(IV)) showed a clear interaction with soluble EGFR, suggesting that EGFR binding site is located in this module. Injection of CCN2(IV) in mice increased EGFR phosphorylation in the kidney, mainly in tubular epithelial cells. EGFR kinase inhibition decreased CCN2(IV)-induced renal changes (ERK activation and inflammation). Studies in cultured tubular epithelial cells showed thatCCN2(IV) binds to EGFR leading to ERK activation and proinflammatory factors overexpression. CCN2 interacts with the neurotrophin receptor TrkA, and EGFR/TrkA receptor crosstalk was found in response to CCN2(IV) stimulation. Moreover, endogenous CCN2 blockade inhibited TGF-β-induced EGFR activation. These findings indicate that CCN2 is a novel EGFR ligand that contributes to renal damage through EGFR signalling. | |
| Rayego-Mateos S, et al. J Mol Cell Biol. 2013 Aug 8. [Epub ahead of print] | |
 |
 |
Human CTGF ELISA |
 |
Human CTGF ELISA Code No.: SK00726-01 Size: 96 T Price: $360.00 USD Standard Range:62.5-4000 pg/ml Sensitivity:10 pg/ml Specificity: C-terminal rh CTGF Sample Type: cell culture, serum, EDTA plasma Sample requres: 100uL per well IntraCV: 6-8% InterCV: 10-12% Protocol: PDF |
 |
Human CTGF ELISA Code No.: SK00726-02 Size: 96 T Price: $360.00 USD Standard Range:31-2000 ng/ml Sensitivity:21ng/ml Sample Type: cell culture, serum, EDTA plasma Sample requres: 100uL per well Specificity: full rh CTGF and C-Terminal fragments (16-21KD) IntraCV: 6-8% InterCV: 10-12% Protocol: PDF |
 |
Anti Human CTGF IgG Code No.: A00726-01-100 Size: 100 ug Price: $22.00 USD Immunogen: human CTGF rec. Host: Rabbit Ab Type:IgG Application E, IHC, WB Working Conc.: 2 ug/ml Carry: free Data Sheet: PDF |
 |
Anti Human CTGF IgG Code No.: A00726-01-100 Size: 100 ug Price: $22.00 USD Immunogen: human CTGF rec. Specificity:Full and C-terminal fragment of human CTGF Host: Rabbit Ab Type:IgG Application E, IHC, WB Working Conc.: 2 ug/ml Carry: free Data Sheet: PDF |
|
Human CTGF,Recombinant Code No.: 00726-01-100 Size: 100 ug Price: $360.00 USD Protein ID:P29279 Gene ID: 1490 MW:34 KD Tag: His Tag on N-Terminus Expressed: E. Coli Purity: 90% Data Sheet: PDF This protein indicated crossreactivity with aviscera bioscience's CTGF elisa kits. But that may not be used as standard for elisa |
| Goat Anti Human CTGF IgG Code No.: A00726-06-100 Size: 100 ug Price: $22.00 USD Immunogen: human CTGF rec. Specificity: full and C-terminal fragment of human CTGF Host: Goat Ab Type:IgG Application E, IHC, WB Working Conc.: 2 ug/ml Carry: free Data Sheet: PDF |
|
|
|
| Name | Code No. |
Size |
Price ($) |
| CTGF (Human) ELISA | 96 T |
360.00 |
|
| CTGF (Human) ELISA | 96 T |
360.00 |
|
| CTGF (Human) ELISA | 96 T |
360.00 |
|
| CTGF (Human) Rec. | 100 ug |
360.00 |
|
| CTGF (Human) Rec. | 00726-01-1000 |
1000 ug |
3200.00 |
| Anti CTGF (Human) IgG | 100 ug |
220.00 |
|
| Anti CTGF (Human) IgG , Biotinylated | 50 ug |
260.00 |
|
| Goat Anti CTGF (Human) IgG | 100 ug |
290.00 |
|
| Goat Anti CTGF (Human) IgG | 200 ug |
420.00 |
|
| Goat Anti CTGF (Human) IgG, biotinylated | 50 ug |
310.00 |
|
| Goat Anti CTGF (Human) IgG, biotinylated | 100 ug |
500.00 |
|
| Goat Anti CTGF (Human) IgG, Cy3 conjugated | A00726-06-50C3 |
50 ug |
460.00 |
| Goat Anti CTGF (Human) IgG, FAM conjugated | A00726-06-50FAM |
50 ug |
390.00 |